4th World Cancer Congress - 2020

CONFERENCE AGENDA

DAY 1: 20:03:2021

DAY 2: 21:03:2021

DAY 2: SUNDAY, 21ST MARCH, 2021

08:00 AM - 09:00 AM

REGISTRATIONS OPENS

09:00 AM - 11:00 AM

CANCER DIAGNOSTICS: FROM CUTTING EDGE TO DAILY REALITY

Earlier and better diagnosis is fundamental to achieving improved outcomes in cancer, and it is therefore heartening to witness revolutionary technological improvements in this area, including liquid biopsies, genetic testing and exciting advances in the field of imaging.

But serious challenges remains in not only bringing these breakthroughs into daily practice, but also separating hype from reality where required, understanding any necessary caveats to their application, meeting new unmet needs (e.g. patient counseling on genetic testing) and considering the challenges to existing service models (e.g. direct to consumer testing and the role of primary care in utilizing new tools for diagnosis).

The Session will focus on:

Cancer screening and early detection and prevention.
Molecular diagnostics.  Personalized genomics and clinical biomarkers.
Digital cancer pathology and imaging
Chemotherapy and biological therapeutics.
Innovational combinational therapies

11:00 AM - 11:10 AM

NETWORKING BREAK

11:10 AM - 01:10 PM

TRANSALATION ONCOLOGY

Translational Oncology forms the bridge between basic research and clinical practice thereby holding the key to the progress in oncology. Tumour heterogeneity, Liquid biopsies, and Immunotherapy play a vital role in Translational Oncology.

The Session will focus on:

Cellular and genetic oncology
Laboratory concepts from bench to bedside
Cancer microenvironment
Cancer trends and Opportunities
Radiation Oncology
World Cancer Market

01:10 PM - 02:00 PM

LUNCH & NETWORKING BREAK

02:00 PM - 04:00 PM

ANTI-CANCER DRUG DISCOVERY

Global Anticancer Drug market size is expected to reach USD 145.2 Billion in 2023, at a CAGR of 6.7% from 2017 to 2023. The growth of the anticancer drug market is attributed to the growing awareness towards cancer diagnosis and treatment, and increasing incidence of targeted disease(cancer, skin cancer, and oral cancer among others),coupled with increasing research and development activities.

The key players dealing in the anticancer drug market are Roche Holding Ltd, Celgene, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Novartis, AstraZeneca, Teva Pharmaceutical, Eli Lilly, Bayer, and GlaxoSmithKline among others.

This Session will focus on:

New Anti-Cancer Drug Development.
Targeted Drug Delivery.
Anticancer Plant-Derived Drugs.
Anti-Cancer Generic Medicine
Herbal and Traditional Anti-Cancer Medicine
Alternative treatments and therapeutics
Quality control and standardization of Anti-Cancer drug

04:00 PM - 04:20 PM

NETWORKING BREAK

04:20 PM - 05:00 PM

CULTURAL EVENTS

05:00 PM - 05:30 PM

AWARD CEREMONY & CLOSING CEREMONY